Severe sepsis: New concepts in pathogenesis and management - Introduction

American Journal of the Medical Sciences

Volumn 328, Issue 4, 2004, Pages 193-195

  Summer, Warren R ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; INSULIN; VASOPRESSIN;

ANALGESIA; CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; EDITORIAL; GENETIC POLYMORPHISM; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; INFLAMMATION; INTENSIVE CARE UNIT; LUNG INJURY; MEDICAL DECISION MAKING; MORTALITY; MULTIPLE ORGAN FAILURE; PATHOGENESIS; Q WAVE; RISK FACTOR; SEPSIS; ST SEGMENT ELEVATION; VASCULAR ENDOTHELIUM;

EID: 5644252875     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200410000-00001     Document Type: Article

References (28)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee. Chest 1992;101:1644-55.
2. Kraus WA, Sun X, Nystrom O, et al. Evaluation of definitions for sepsis. Chest 1992;101:1656-62.
3. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. Intens Care Med 1996;22:707-10.
4. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29:S109-16.
5. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998;26: 2078-86.
6. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers: Academic Medical Center Consortium Sepsis Project Working Group. JAMA 1997;278:234-40.
7. Opal SM, Cohen J. Clinical Gram-positive sepsis: does it fundamentally differ from Gram-negative bacterial sepsis? Crit Care Med 1999;27:1608-16.
8. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
9. Netea NG, Van der Meer JW, Van Deuren, et al. Proinflammatory cytokines and sepsis syndrome: not enough, or too much of a good thing? Trends Immunol 2003;24:254-8.
10. Beutler B. Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock. New Horizons 1993;1: 3-12.
11. Pittet D, Harbarth S, Suter PM, et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am J Respir Crit Care Med 1999;160:852-7.
12. Vervloet MG, Thijis LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998;24:33-44.
13. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis shock, and multiple organ dysfunction. Crit Care Med 1999;27:1230-51.
14. De Backer D, Creteur J, Preisler JC, et al. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002;166:98-104.
15. Bone RC, Francis PB, Peirce AK. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med 1976;61:585-9.
16. Ueno H, Hirasawa H, Oda S, et al. Coagulation/fibrinolysis abnormality and vascular endothelial damage in the pathogenesis of thrombocytopenic multiple organ failure. Crit Care Med 2002;30:2242-8.
17. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
18. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 1993;103:565-75.
19. Russell J, Singer J, Bernard G, et al. Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 2000;28:3405-11.
20. Aljada A, Ghanim H, Mohanty P, et al. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002;87:1419-22.
21. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-67.
22. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low does of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-71.
23. Chen P. Vasopressin: New uses in critical care. Am J Med Sci 2002;324:146-54.
24. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. New Engl J Med 2004;350:1629-38.
25. Dellinger RP, Carlet JM, Masur H, et al., for the Surviving Sepsis Campaign Management Guidelines Committee. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-73.
26. Clarke EB, Curtis JR, Luce JM, et al., for the Robert Wood Johnson Foundation Critical Care End of-Life Peer Workgroup Members. Quality indicators for end-of-life care in the intensive care unit. Crit Care Med 2003;31: 2255-62.
27. Berger JT. Ethical challenges of partial do-not-resuscitate (DNR) orders. Placing DNR orders in the context of a life treating condition plan. Arch Intern Med 2003;163:2270-5.
28. Romberg E, Passler H, Brahms C, et al. Untersuchungen über die allgemeine Pathologie and Therapie der Kreislaufstörung der akuten Infectionskrankheiten. Dtsch Arch Klin Med 1899;64:652.